Why the study?
Does low molecular weight heparin cause hepatotoxicity in patients treated for thromboembolic events?
Does low molecular weight heparin cause hepatotoxicity in patients treated for thromboembolic events?
Low molecular weight heparin can induce complement-mediated hepatotoxicity that resolves upon discontinuation of the drug.
Answers are grounded in this paper and cite their sources.
May indicate LMWH-induced complement-mediated hepatotoxicity resolving on discontinuation; leaves open causality in thromboembolic patients.
The authors report two cases of hepatotoxicity induced by low molecular weight heparin. A 26-year-old woman and a 33-year-old man were treated with low molecular weight heparin for pulmonary embolism and cerebral infarction, respectively. They both developed derangement in liver function tests a few days after commencement of the low molecular weight heparin. The derangement in liver function tests was associated with a decreased serum complement 3 activity. Their liver functions recovered over a period of 2 to 3 months after low molecular weight heparin was stopped. Liver biopsy in the woman demonstrated balloon degeneration with scattered foci of hepatocytic necrosis, suggesting a complement-mediated hepatocellular damage.
No takes yet. Share an insight, caveat, or question.
Hui et al. (2001) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: